Compare Stocks: SDZNY, BMY, SNY, and GSK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$66.85 -1.8%	$62.92	$42.52 ▼ $68.64	$136.49B	0.23	8.25 million shs	4.79 million shs
GSK GSK	$49.88 -1.9%	$51.70	$39.29 ▼ $61.69	$100.91B	0.35	2.94 million shs	2.29 million shs
SDZNY Sandoz Group	$84.34 -3.6%	$85.55	$55.42 ▼ $94.15	$37.11B	0.57	16,527 shs	11,030 shs
SNY Sanofi	$44.24 -0.2%	$43.92	$40.89 ▼ $52.68	$107.26B	0.35	2.31 million shs	1.69 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	0.00%	+0.35%	+4.14%	+16.80%	+40.80%
GSK GSK	0.00%	-1.81%	-4.34%	-3.27%	+26.73%
SDZNY Sandoz Group	0.00%	-0.94%	-0.94%	+4.59%	+36.68%
SNY Sanofi	0.00%	-1.29%	+3.15%	-1.73%	-11.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$66.85 -1.8%	$62.92	$42.52 ▼ $68.64	$136.49B	0.23	8.25 million shs	4.79 million shs
GSK GSK	$49.88 -1.9%	$51.70	$39.29 ▼ $61.69	$100.91B	0.35	2.94 million shs	2.29 million shs
SDZNY Sandoz Group	$84.34 -3.6%	$85.55	$55.42 ▼ $94.15	$37.11B	0.57	16,527 shs	11,030 shs
SNY Sanofi	$44.24 -0.2%	$43.92	$40.89 ▼ $52.68	$107.26B	0.35	2.31 million shs	1.69 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	0.00%	+0.35%	+4.14%	+16.80%	+40.80%
GSK GSK	0.00%	-1.81%	-4.34%	-3.27%	+26.73%
SDZNY Sandoz Group	0.00%	-0.94%	-0.94%	+4.59%	+36.68%
SNY Sanofi	0.00%	-1.29%	+3.15%	-1.73%	-11.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol Myers Squibb	2.56	Moderate Buy	$66.06	-1.19% Downside
GSK GSK	2.10	Hold	$53.00	6.26% Upside
SDZNY Sandoz Group	3.60	Strong Buy	N/A	N/A
SNY Sanofi	2.40	Hold	$49.50	11.89% Upside

Current Analyst Ratings Breakdown

Latest SDZNY, BMY, SNY, and GSK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	SDZNY Sandoz Group	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/25/2026	GSK GSK	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Underweight
8/18/2026	BMY Bristol Myers Squibb	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/5/2026	BMY Bristol Myers Squibb	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform ➝ Strong-Buy
8/5/2026	BMY Bristol Myers Squibb	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold ➝ Buy
8/5/2026	BMY Bristol Myers Squibb	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/5/2026	BMY Bristol Myers Squibb	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/5/2026	BMY Bristol Myers Squibb	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$75.00
8/5/2026	BMY Bristol Myers Squibb	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
8/5/2026	BMY Bristol Myers Squibb	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
8/5/2026	BMY Bristol Myers Squibb	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$75.00

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol Myers Squibb	$48.19B	2.83	$7.99 per share	8.37	$10.93 per share	6.12
GSK GSK	$33.20B	3.04	$5.89 per share	8.47	$11.40 per share	4.38
SDZNY Sandoz Group	$11.09B	3.35	$3.48 per share	24.24	$21.33 per share	3.95
SNY Sanofi	$48.92B	2.19	$7.06 per share	6.27	$33.36 per share	1.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol Myers Squibb	$7.05B	$4.54	14.72	10.38	0.32	18.87%	66.90%	14.74%	10/29/2026 (Estimated)
GSK GSK	$7.54B	$3.20	15.60	9.88	1.99	14.56%	43.23%	11.60%	10/28/2026 (Estimated)
SDZNY Sandoz Group	$914M	N/A	N/A	18.14	1.84	N/A	N/A	N/A	N/A
SNY Sanofi	$8.84B	$1.91	23.16	8.41	1.34	8.66%	14.19%	7.95%	10/23/2026 (Estimated)

Latest SDZNY, BMY, SNY, and GSK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2026	Q2 2026	BMY Bristol Myers Squibb	$1.60	$2.04	+$0.44	$1.62	$11.74 billion	$12.97 billion
7/30/2026	Q2 2026	SNY Sanofi	N/A	$2.41	N/A	$0.17	N/A	$13.36 billion
7/28/2026	Q2 2026 & Strategy update	GSK GSK	$1.27	$1.36	+$0.09	$0.28	$11.02 billion	$11.14 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol Myers Squibb	$2.52	3.77%	+1.61%	55.51%	17 Years
GSK GSK	$1.77	3.55%	-7.86%	55.31%	N/A
SDZNY Sandoz Group	$0.61	0.72%	N/A	N/A	N/A
SNY Sanofi	$1.76	3.98%	+6.46%	92.15%	N/A

Latest SDZNY, BMY, SNY, and GSK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/28/2026	GSK GSK	quarterly	$0.4515	3.65%	8/14/2026	8/14/2026	10/8/2026
6/17/2026	BMY Bristol Myers Squibb	quarterly	$0.63	4.34%	7/2/2026	7/2/2026	8/3/2026
1/1/2100	GSK GSK	quarterly	$0.4206	4.3%	8/15/2025	8/15/2025	10/9/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol Myers Squibb	1.89	1.53	1.38
GSK GSK	0.81	0.82	0.52
SDZNY Sandoz Group	0.53	1.18	0.77
SNY Sanofi	0.21	0.99	0.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol Myers Squibb	76.41%
GSK GSK	15.74%
SDZNY Sandoz Group	0.05%
SNY Sanofi	14.03%

Insider Ownership

Company	Insider Ownership
BMY Bristol Myers Squibb	0.05%
GSK GSK	10.00%
SDZNY Sandoz Group	N/A
SNY Sanofi	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol Myers Squibb	32,500	2.04 billion	2.04 billion	Optionable
GSK GSK	66,841	2.02 billion	1.82 billion	Optionable
SDZNY Sandoz Group	23,567	440.00 million	N/A	Not Optionable
SNY Sanofi	74,846	2.42 billion	2.40 billion	Optionable

SDZNY, BMY, SNY, and GSK Headlines

Recent News About These Companies

Sanofi (NASDAQ:SNY) Receives Average Recommendation of "Hold" from Brokerages

September 2, 2026 | americanbankingnews.com

Sanofi (NASDAQ:SNY) Upgraded at Wall Street Zen

August 29, 2026 | americanbankingnews.com

Sanofi (NASDAQ:SNY) Rating Increased to Buy at Wall Street Zen

August 29, 2026 | marketbeat.com

SNY Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?

August 28, 2026 | zacks.com

Sanofi (NASDAQ:SNY) Receives Average Rating of "Hold" from Analysts

August 28, 2026 | marketbeat.com

US FDA approves updated COVID vaccines for 2026-27 season

August 27, 2026 | reuters.com

Sanofi stock steadies after strong Q2 2026 and upgraded guidance

August 21, 2026 | ad-hoc-news.deA

The Manufacturers Life Insurance Company Lowers Position in Sanofi $SNY

August 12, 2026 | marketbeat.com

Dimensional Fund Advisors LP Trims Stock Holdings in Sanofi $SNY

August 12, 2026 | marketbeat.com

Why the Amlitelimab Setback Isn’t Enough to Sink Sanofi’s Multi-Billion Dollar Engine

August 10, 2026 | insidermonkey.com

Why the Amlitelimab Setback Isn’t Enough to Sink Sanofi’s Multi-Billion Dollar Engine

August 10, 2026 | finance.yahoo.com

Sanofi (NASDAQ:SNY) Cut to "Hold" at Wall Street Zen

August 9, 2026 | marketbeat.com

Sanofi 2026 Q2 - Results - Earnings Call Presentation

August 7, 2026 | seekingalpha.com

Sanofi Says EU Expands MenQuadfi Approval

August 5, 2026 | finance.yahoo.com

Sanofi’s MenQuadfi approved in EU for infants against meningococcal disease

August 5, 2026 | msn.com

Why Investors Should Look at L3Harris, Cenovus, and Sanofi

August 5, 2026 | baystreet.ca

Press Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease

August 4, 2026 | manilatimes.netM

Press Release: Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease

August 4, 2026 | globenewswire.com

Sanofi SA (SNY) (Q2 2026) Earnings Call Highlights: Strong Sales Growth and Upgraded Guidance ...

August 1, 2026 | sg.finance.yahoo.com

Sanofi says weak decision-making hurt pipeline, promises more disciplined R&D

July 30, 2026 | msn.com

Press Release: Sanofi’s half-year financial report for 2026

July 30, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SDZNY, BMY, SNY, and GSK Company Descriptions

Bristol Myers Squibb NYSE:BMY

$66.85 -1.24 (-1.82%)

As of 09/4/2026 03:58 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

GSK NYSE:GSK

$49.88 -0.99 (-1.95%)

As of 09/4/2026 03:58 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Sandoz Group OTCMKTS:SDZNY

$84.34 -3.19 (-3.64%)

As of 09/4/2026 03:59 PM Eastern

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

Sanofi NASDAQ:SNY

$44.24 -0.09 (-0.20%)

As of 09/4/2026 04:00 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SDZNY, BMY, SNY, and GSK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SDZNY, BMY, SNY, and GSK Earnings

Compare Dividends

Latest SDZNY, BMY, SNY, and GSK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SDZNY, BMY, SNY, and GSK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SDZNY, BMY, SNY, and GSK Company Descriptions

Bristol Myers Squibb NYSE:BMY

GSK NYSE:GSK

Sandoz Group OTCMKTS:SDZNY

Sanofi NASDAQ:SNY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SDZNY, BMY, SNY, and GSK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SDZNY, BMY, SNY, and GSK Earnings

Compare Dividends

Latest SDZNY, BMY, SNY, and GSK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SDZNY, BMY, SNY, and GSK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SDZNY, BMY, SNY, and GSK Company Descriptions

Bristol Myers Squibb NYSE:BMY

GSK NYSE:GSK

Sandoz Group OTCMKTS:SDZNY

Sanofi NASDAQ:SNY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools